Xenetic Biosciences Inc Stock Price, News & Analysis

Xenetic Biosciences (NASDAQ: XBIO) reported its first quarter 2022 financial results, highlighting a net loss of approximately $1.6 million and cash reserves of $16.2 million. The company has completed an exclusive licensing agreement with CLS Therapeutics for a DNase-based oncology platform aimed at enhancing cancer treatment outcomes. The focus is on advancing this platform for Phase 1 clinical development targeting locally advanced or metastatic solid tumors, with an IND filing anticipated by the end of 2023.

Xenetic Biosciences (NASDAQ: XBIO) has announced a transaction with CLS Therapeutics to develop a DNase-based oncology platform, which aims to enhance the efficacy of existing therapies for solid tumors. This includes an exclusive license for DNases in cancer treatment, entailing an upfront payment of $500,000, issuance of shares, and future milestone payments potentially reaching $13 million. The company plans to conduct a Phase 1 clinical study targeting locally advanced or metastatic cancers. The platform seeks to address issues related to Neutrophil Extracellular Traps (NETs), which may hinder cancer treatment outcomes.

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of $5.6 million for the year ended December 31, 2021, with research and development expenses rising to $3.2 million. The company ended the year with cash reserves of approximately $18.2 million and working capital of about $17.3 million, up from $11.4 million in 2020. Their XCART platform is advancing toward IND-enabling studies, while royalty payments from the PolyXen technology reached $1.2 million, a 166% increase from the previous year. The XCART program targets a potential global market of over $7 billion annually.

Xenetic Biosciences (NASDAQ: XBIO) is advancing its XCART platform towards IND-enabling studies, backed by a strengthened cash position from a recent $12.5 million private placement. The company reported a net loss of $1.4 million for Q3 2021, with R&D expenses rising by 36.1% to $0.8 million. Additionally, royalty streams have grown through its license agreement with PolyXen^®, bringing in approximately $0.3 million in royalties. With working capital at $19.5 million, Xenetic is positioned to pursue its innovative cancer therapies effectively.

Xenetic Biosciences (NASDAQ: XBIO) announced a Notice of Allowance from the USPTO for its patent application covering its XCART personalized CAR T therapy. This platform targets tumor-specific neoantigens and aims to improve cancer treatment effectiveness. CEO Jeffrey Eisenberg highlighted this as a significant milestone for the XCART program, which is currently in pre-clinical development for Non-Hodgkin lymphoma. The resulting U.S. patent is expected to expire in 2038, enhancing the company's intellectual property portfolio.

Xenetic Biosciences (NASDAQ: XBIO) has announced that CEO Jeffrey F. Eisenberg will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the Company's personalized CAR T platform technology, XCART™, designed to target patient-specific tumor neoantigens. A video webcast of the presentation will be available on-demand starting September 13 at 7:00 AM ET, with a replay accessible for 90 days. The Company is also leveraging its PolyXen® platform for drug delivery improvements.

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of approximately $1.1 million for Q2 2021, with R&D expenses increasing 70.4% to $0.5 million due to advancements in its XCART platform. The company strengthened its position through a $12.5 million private placement and saw royalty growth from its PolyXen technology, totaling about $0.3 million in royalties generated from Takeda's sublicensee. The company is progressing towards IND-enabling studies in the U.S., aiming to address a significant market opportunity in oncology.

Xenetic Biosciences (NASDAQ: XBIO) announced the closure of a private placement, raising approximately $12.5 million by issuing 4,629,630 shares at $2.70 each. The offering included warrants that could generate an additional $15.3 million if fully exercised. Proceeds will be used for general working capital. The shares were sold under a private placement exemption and the company plans to register them within 30 days. Xenetic focuses on advancing its XCART technology for cancer treatment and leveraging its PolyXen drug delivery platform.

Xenetic Biosciences (NASDAQ: XBIO) has announced a definitive agreement for a private placement with a healthcare-focused institutional investor. The transaction involves the sale of 4,629,630 shares of common stock at $2.70 per share, amounting to $12.5 million in gross proceeds. The investor will also receive warrants to purchase an equal number of shares at $3.30 per share. The placement is expected to close around July 28, 2021. The funds will be utilized for general working capital purposes, aiding the advancement of their XCART technology for cancer treatment.